F-1/A: Cuprina Holdings Eyes Nasdaq Listing with $15.9 Million IPO

Cuprina Holdings, a Singapore-based biomedical firm, plans to raise capital through an initial public offering of Class A Ordinary Shares on the Nasdaq Capital Market.

Summary

• Cuprina Holdings (Cayman) Limited is planning an initial public offering (IPO) of 3,750,000 Class A Ordinary Shares.
• The company anticipates the initial public offering price will be between US$4.00 and US$4.50 per share, potentially raising approximately $15.9 million.
• Cuprina intends to use the net proceeds for growth and expansion into new markets, research and development, building brand awareness, investment in equipment and infrastructure, and loan repayment.
• The company is an emerging growth company and an exempted company incorporated in the Cayman Islands.
• R. F. Lafferty & Co., Inc. is the underwriter for the offering and has a 45-day option to purchase up to 562,500 additional Class A Ordinary Shares.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The closing of the initial public offering is conditioned upon Nasdaqs final approval of our listing application.
• Immediately prior to the completion of this offering, we will have 3,915,000 Class A Ordinary Shares and 14,085,000 Class B Ordinary Shares issued and outstanding.

Sentiment

Score: 6

Explanation: The document is factual and descriptive, outlining the company's plans for an IPO. While it acknowledges risks, it also highlights the company's strengths and growth strategies. The sentiment is neutral to slightly positive.

Positives

• The company has strategic plans in place for 2025 and 2026 to expand its sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China.
• The company has been granted an exclusive license from NTUitive Pte. Ltd., a wholly owned subsidiary of Nanyang Technological University, to develop and commercialize a range of chronic wound care products using collagen derived from bullfrog skin.
• The company has attained ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for its manufacturing facility located in Singapore in 2020.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021, 2022, 2023 and June 30, 2024, and such positions may continue after this offering.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022, 2023, and six months ended June 30, 2024.

Risks

• The company's business and future growth prospects rely on industry development and consumer demand for its products.
• The company's revenue growth for a particular period is difficult to predict, and a shortfall in forecasted revenues may harm its operating results.
• Failure to manage the company's growth strategy could harm its business.
• If the company is unable to compete within its markets or its products do not gain market acceptance, its financial condition and operating results could suffer.
• Security breaches and other disruptions could compromise the company's information and expose it to liability, which would cause its business and reputation to suffer.
• The company relies heavily on its R&D partners for know-how on design, manufacturing methods and formulation of its products.
• The development and sale of certain of the company's pipeline products are heavily dependent on certain agreements with R&D partners and the termination of any of these agreements could harm its business.
• Certain of the company's pipeline products are still under development and it may not be able to successfully commercialize any of these product candidates.
• It may be difficult for investors to enforce any judgment obtained in the United States against the company, its directors, executive officers or its affiliates.
• An active trading market for the company's Class A Ordinary Shares may not be established or, if established, may not continue and the trading price for its Class A Ordinary Shares may fluctuate significantly.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject it to additional trading restrictions.
• The trading price of the company's Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.

Future Outlook

The company has strategic plans in place for 2025 and 2026 to expand its sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China.

Industry Context

The company operates in the biomedical and biotechnology industry, focusing on chronic wound care and cosmeceuticals. The chronic wound care market is driven by an aging population and increasing prevalence of comorbidities like diabetes and obesity.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• It mentions competitors like Smith & Nephew plc, ConvaTec Group plc, Mlnlycke Health Care AB, 3M, Integra Urgo Group, but does not offer a detailed comparison of financial performance or market share.

Related Party Transactions

• The document mentions loan repayment to one of the company's ultimate beneficial shareholders, Jimmy Lee Peng Siew, who provided advances for working capital purposes.
• Cuprina Holding Pte. Ltd. gave advances to the company for working capital purposes.

Stakeholder Impact

• Shareholders: Potential for capital appreciation and influence on corporate matters.
• Employees: Potential for job creation and career advancement.
• Customers: Access to innovative wound care and cosmeceutical products.
• Suppliers: Potential for increased business opportunities.
• Creditors: Increased financial stability and ability to repay debts.

Next Steps

• Secure Nasdaq listing approval.
• Execute the IPO and receive net proceeds.
• Implement the outlined plans for expansion, R&D, and marketing.

Key Dates

Keywords

Class A Ordinary Shares, IPO, Cuprina Holdings, Medical Devices, Wound Care, Nasdaq, R. F. Lafferty & Co.